Related Experiment Videos
Laparoscopy-assisted distal gastrectomy with systemic lymph node dissection: a phase II study following the learning
Michitaka Fujiwara1, Yasuhiro Kodera, Shinichi Miura
1Department of Surgery II, Nagoya University School of Medicine, Nagoya/Aichi, Japan.
Journal of Surgical Oncology
|July 7, 2005
Summary
Laparoscopy-assisted distal gastrectomy (LADG) is a safe and feasible approach for early-stage gastric cancer, significantly reducing morbidity and hospital stay. Experienced surgeons can overcome the learning curve for this effective treatment.
Area of Science:
- Surgical Oncology
- Minimally Invasive Surgery
- Gastrointestinal Surgery
Background:
- Preliminary studies indicated higher morbidity with laparoscopy-assisted approaches for gastric carcinoma.
- Gastric cancer treatment necessitates safe and effective surgical techniques.
Purpose of the Study:
- To prospectively evaluate the safety and efficacy of laparoscopy-assisted distal gastrectomy (LADG) for early-stage gastric cancer.
- To compare outcomes of LADG with a previous series to assess improvements in surgical parameters.
Main Methods:
- A prospective phase II study involving 47 patients with T1 N0 stage gastric cancer.
- Patients underwent LADG for tumors in the lower or middle-third stomach.
- Key outcomes recorded included blood loss, operating time, mortality, morbidity, and lymph node retrieval.
Main Results:
- Significant reductions in mean blood loss and postoperative hospital stay were observed compared to the preliminary series.
- No in-hospital deaths occurred, and the incidence of anastomotic leakage was significantly decreased.
- All patients remained disease-free post-surgery, indicating positive oncological outcomes.
Conclusions:
- Laparoscopy-assisted distal gastrectomy (LADG) is a safe procedure for gastric cancer surgery when performed by experienced surgeons past the learning curve.
- Morbidity is no longer a significant drawback, making LADG feasible for early-stage gastric cancer.
- Further investigation into the applicability of LADG for T2 stage gastric cancer is warranted.